This page uses content from Wikipedia and is licensed under CC BY-SA.

Cofetuzumab pelidotin

Cofetuzumab pelidotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetprotein tyrosine kinase 7
Clinical data
Other namesPF-06647020
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6774H10418N1778O2096S46
Molar mass151776.97 g·mol−1

Cofetuzumab pelidotin (INN[1]; development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer.[2] The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.[3][4]

Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug that then kills the cells. This allows the drug to selectively target the cells that the antibody binds to.

PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer.[5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.[6]

References

  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin, American Medical Association.
  3. ^ "PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
  4. ^ "Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
  5. ^ [www.pfizer.com]
  6. ^ Patrick, Margaret (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. Retrieved 2017-05-22.